Incidence of Hypertension Associated With Poly-Adp-Ribose Polymerase (Parp) Inhibitors in Combination With Antiangiogenic Drugs: A Meta-Analysis

Objective: poly-ADP-ribose polymerase(PARP) inhibitors have demonstrated significant anti-tumor activity in a variety of tumors, such as ovarian cancer, and some studies have found that PARP inhibitors combined with anti-angiogenic drugs have achieved significant results in the treatment of ovarian cancer compared with single drugs. While there are few studies on the vascular safety of the combination of PARP inhibitors and anti-angiogenic drugs. Therefore, We conducted a meta-analysis to assess the incidence of hypertension in patients with ovarian cancer treated with PARP inhibitors in combination with anti-angiogenic agents. Design and method: We reviewed PubMed, Embase, Cochrane Library and Web of Science databases to identify relevant randomised controlled trials published from inception to November 10, 2023, without language restrictions. Randomised controlled trials (RCTs) of patients with Ovarian Cancer treated with PARP inhibitors in combination with anti-angiogenic inhibitors in the experimental group, as well as available data on treatment-induced increases in blood pressure. Results: Five studies were selected for the final analysis, The incidence of PARP inhibitors plus anti-angiogenic agents related hypertension from 38.8% to 79.5%, compared from 0% to 59.9% in the control groups, PARP inhibitors plus anti-angiogenic agents therapies significantly increased the risk of hypertension (random-effects, OR = 10.38; P =0.04). Conclusions: PARP inhibitors combined with antiangiogenic inhibitors increase the risk of hypertension.